Avacta Group Plc · LSE:AVCT
Avacta — Investor Presentation (March 2025)
28 slides from Avacta's investor presentation, March 2025
Slide 1: Expanding the reach of highly potent cancer therapies
Expanding the reach of highly potent cancer therapies March 2025
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s research, preclinical and clinical development activities, plans and projected timelines for AVA6000 and the Avacta pipeline, plans re
Slide 3: Avacta Therapeutics: Pioneering a novel, differentiated class of pre|CISION medicines
Avacta Therapeutics: Pioneering a novel, differentiated class of pre|CISION® medicines to revolutionize drug delivery Innovative pre|CISION® The pre|CISION® Company Platform Pipeline Positioning • pre|CISION® targets delivery of payload • AVA6000 (FAP-Dox) Phase I completed: • AIM-listed (#AVCT) pur
Slide 4: The pre|CISION Peptide Drug Conjugate Platform Delivers Potent Payloads Directly to Tumors
The pre|CISION® Peptide Drug Conjugate (PDC) Platform Delivers Potent Payloads Directly to Tumors and Spares Normal Tissues The challenge in oncology is that 100 our most effective therapies cause Therapeutic Percent of Patients Responding the most toxicity in normal tissues 80 window Efficacy Toxic
Slide 5: The Avacta Leadership Team: Proven Track Record
The Avacta Leadership Team: Proven Track Record Christina Coughlin, Brian Hahn, Simon Bennett, Karen Harrison Michelle Morrow, MD, PhD MBA DPhil PhD Chief Executive Officer Chief Financial Officer Chief Business Officer Chief Operating Officer Chief Scientific Officer and Head of R&D Chris is an onc
Slide 6: The pre|CISION Peptide Drug Conjugates Unleash Potent Drugs Selectively in the Tumor
The pre|CISION® Peptide Drug Conjugates Unleash Potent Drugs Selectively in the Tumor through Masking and Release The pre|CISION peptide masks pre|CISION peptide cleavage releases 1 3 the toxic effects of active payload in the extracellular a payload in the tissues space, optimizing the bystander ef
Slide 7: The pre|CISION Mechanism of Action: the Bystander Effect
The pre|CISION® Mechanism of Action: the Bystander Effect Tumor cell intracellular space Released payload peptide Released (free) payload enters FAP- tumor or FAP+ CAF cells Peptide drug conjugate cannot enter cells Tumor: Stroma Interface The pre|CISION peptide binds in the active site of FAP and i
Slide 8: Our Strategic Partnership with Tempus AI Has Defined the Market Opportunity
Our Strategic Partnership with Tempus AI Has Defined the Market Opportunity with pre|CISION Medicines RNAseq data corresponds to IHC 2-3+ Global incidence of TNBC: 170,000 FAP+: 161,000 100 RNAseq data FAP high: 136,000 corresponds Percent tumor samples Global incidence of mSGC: ~15,000 to IHC 1+ FA
Slide 9: Avacta: Highly Differentiated Pipeline
Avacta: Highly Differentiated Pipeline Platform/ Potential Ind- Program Warhead Indications Preclinical enabling Phase 1 Phase 2 Milestones Head and Neck Cancers Expansion cohorts (Salivary Gland Ca subset) pre|CISION to enroll in 2025 AVA6000 High grade sarcoma Doxorubicin Ph Ia data update (Dediff
Slide 10: FAP-Dox (AVA6000): pre|CISION-enabled doxorubicin
FAP-Dox (AVA6000): pre|CISION-enabled doxorubicin Phase 1 results and path forward 10
Slide 11: AVA6000 Phase 1 Trial Design and Patient Population
AVA6000 Phase 1 Trial Design and Patient Population Doses analyzed for efficacy PHASE 1: ARM 1 EXPANSION COHORTS Q3W iv 80 [54] 120 [81] 160 [108] 200 [135] 250 [169] 310 [209] 385 [260] (PHASE 1B) [dox equivalent] N=4 N=6 N=8 N=7 N=9 N=6 N=4 (mg/m2) Conventional escalated dose Triple Negative Breas
Slide 12: AVA6000 has Dramatically Reduced the Toxic Effects Associated with Doxorubicin
AVA6000 has Dramatically Reduced the Toxic Effects Associated with Doxorubicin and the ADC Drug Class AVA6000 demonstrates no severe cardiac toxicity (compared to conventional doxorubicin) • Bone marrow toxicities are dramatically reduced when comparing AVA6000 versus conventional dose doxorubicin S
Slide 13: AVA6000: Preliminary Data Demonstrate Durable Tumor Shrinkage in Salivary Gland Cancers
AVA6000: Preliminary Data Demonstrate Durable Tumor Shrinkage in Patients with Salivary Gland Cancers 80 60 sum of the longest diameters Best percent change in the 40 disease 20 progression 0 * * * * * * * * * -20 partial -40 response -60 Salivary gland cancer * Pts with ongoing treatment * Pts reac
Slide 14: AVA6000 demonstrates multiple minor responses, a disease control rate over 90%
AVA6000 demonstrates multiple minor responses, a disease control rate over 90% and median PFS not reached Phase 1a Partial Response Death AVA6000 Treatment Stable Disease Discontinued PFS/OS Follow up Disease Progression Ongoing * Minor response 0 20 40 60 80 100 Weeks of Treatment/Follow-up Data cu
Slide 15: AVA6000 Results in Complete Regression of Large Skin Metastasis
AVA6000 Results in Complete Regression of Large Skin Metastasis in a Patient with a Minor Response Left parotid mass Skin metastasis (upper chest) Initial minor RECIST response with dramatic regression of large skin metastasis: 74 –year-old male with SGC Despite mid level of FAP expression Prior the
Slide 16: Unparalleled Concentration of Payload in the Tumor with FAP-Dox Compared to Conventional Doxorubicin
Unparalleled Concentration of Payload in the Tumor with FAP-Dox (AVA6000) Compared to Conventional Doxorubicin Released Doxorubicin Concentration Tumor to plasma ratio of active 24 hr After the First Dose of AVA6000 doxorubicin after a single dose 10000 Patients with FAPhigh 1000 p<0.0001 ** Patient
Slide 17: AVA6000 Clinical Development: Rapid route to market in an orphan indication
AVA6000 Clinical Development: Rapid route to market in an orphan indication with TNBC to expand the label EA R LY SG C IN D I CA T IO N : T N B C : SE C O N D D E VE L O PME N T F IR ST A PPR O V A L A PPR O V A L Salivary gland cancer (SGC) Indication Phase I Phase II / III Phase Phase I I expansio
Slide 18: Commercial Analysis of AVA6000 Reveals Advantages to the Initial Orphan Indication
Commercial Analysis of AVA6000 Reveals Advantages to the Initial Orphan Indication Supporting the Breast Cancer Indication Salivary Gland Cancer (SGC) Triple Negative Breast Cancer (TNBC) HR+ and HER2+ Breast Cancer Addressable Population 1L/2L Indication 1L/2L (US population estimates) Label expans
Slide 19: FAP-Exd (AVA6103): pre|CISION-enabled exatecan
FAP-Exd (AVA6103): pre|CISION-enabled exatecan Potent Topoisomerase I Peptide Drug Conjugate 19
Slide 20: Exatecan is an ideal payload for the next evolution of the pre|CISION platform
Exatecan is an ideal payload for the next evolution of the pre|CISION platform Potency of Topo I 1 Exatecan (EXd) is the most potent topo I inhibitor with single agent inhibitor class activity in Ph 2 trials in several key FAP-positive indications (breast, gastric, small cell lung cancer) Exatecan (
Slide 21: The FAP-EXd chemistry is designed for sustained, tumor-specific release of highly potent payloads
The FAP-EXd (AVA6103) chemistry is designed for sustained, tumor- specific release of highly potent payloads pre|CISION-Dox (FAP-Dox) in the FAP Docking Model pre|CISION-Exd (FAP-EXd) in the FAP Docking Model Capping pre|CISION Self- pre|CISION group ® peptide immolative cleavage site linker pre|CIS
Slide 22: FAP-EXd (AVA6103) Optimizes Tumor-Specific Delivery with Key Attributes
FAP-EXd (AVA6103) Optimizes Tumor-Specific Delivery with Key Attributes • The MTD of FAP-EXd is 75x that of conventional exatecan (30x molar ratio of pure payload) Optimized Dosing of exatecan allowing greater concentration of exatecan in the tumor • FAP-EXd is completely inert in the absence of FAP
Slide 23: FAP-EXd: Effective killing of FAP-negative tumor cells in 3D culture only with FAP-positive CAF
FAP-EXd (AVA6103): Effective killing of FAP-negative tumor cells in the 3D culture only in the presence of FAP-positive CAF Bystander Effect Spheroid Coculture Demonstrates FAP-enablement of FAP-EXd • FAP-dependent killing was determined using a 3D spheroid model with FAP- breast cancer cells GFP+tu
Slide 24: FAP-EXd Demonstrates Complete Responses in a Topo I-resistant PDX Model of Gastric Cancer
FAP-EXd Demonstrates Complete Responses in a Topo I-resistant PDX Model of Gastric with FAP Expression Only on Murine CAFs FAP-EXd (AVA6103) Treatment Results in FAP-EXd (AVA6103) Results in Complete Responses Complete Responses in a low-FAP Model 2.50 Vehicle Exatecan FAP-EXd (AVA6103) 2.00 100 100
Slide 25: AVA6103 Induces Complete Regression in a PDX Exatecan-refractory Model of Sarcoma
AVA6103 Induces Complete Regression in a PDX Exatecan-refractory Model of Sarcoma with Endogenous Tumor Cell FAP Expression FAP-EXd (AVA6103) Treatment Results in Complete Responses in a low-FAP Model FAP-EXd (AVA6103) Results in Complete Responses 2.00 Vehicle Exatecan FAP-EXd 1.75 (AVA6103) 150 15
Slide 26: FAP-EXd (AVA6103) Planned for Phase 1 to Initiate in Q1 2026
FAP-EXd (AVA6103) Planned for Phase 1 to Initiate in Q1 2026 2024 2025 2026 2027 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Candidate selection IND GMP DS GMP DP manufacture manufacture Dose range GLP toxicology Phase 1 first Milestones Phase finding studies finding studies patient in (FPI) and Key 1ini
Slide 27: pre|CISION IP Aligns with Product Pipeline
pre|CISION® IP Aligns with Product Pipeline: Foundational IP and Program Advances Form the IP Strategy pre|CISION® Platform Foundational IP The background platform IP of the pre|CISION® FAP-cleavable peptide drug conjugates is owned by Bach Bio with an exclusive license to Avacta. Patent expiry in 2
Slide 28: Thank You
Thank You © AVACTA LIFE SCIENCES LIMITED 2024